Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;64(1):e15285.
doi: 10.1111/ped.15285.

Rituximab-induced Crohn's disease in a child with refractory nephrotic syndrome

Shuhei Machida  1 , Soya Kobayashi  1 , Toshifumi Yodoshi  1   2
Affiliations

Rituximab-induced Crohn's disease in a child with refractory nephrotic syndrome

Shuhei Machida et al. Pediatr Int. 2022 Jan.
No abstract available

Keywords: Crohn's disease; inflammatory bowel disease; nephrotic syndrome; rituximab; ustekinumab.

PubMed Disclaimer

References

    1. Shankar U, Vijayasekar K, Bansal R, Walfish A. Treatment of rituximab-induced Crohn's disease with Ustekinumab induction and long-term maintenance of remission. Inflamm. Bowel Dis. 2020; 26: e3.
    1. Del Sordo R, Lougaris V, Bassotti G, Armuzzi A, Villanacci V. Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): a review on etiological and pathogenetic aspects. Clin. Immunol. 2022; 234: 108916.
    1. Uzzan M, Ko HM, Rosenstein AK, Pourmand K, Colombel JF, Mehandru S. Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells. Ann. N. Y. Acad. Sci. 2018; 1415: 5-10.
    1. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 2007; 13 (11): 1365-8.
    1. Mauri C, Menon M. Human regulatory B cells in health and disease: Therapeutic potential. J. Clin. Invest. 2017; 127: 772-9.

LinkOut - more resources